TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022. As a result, the tender offer has expired according to its terms. Th

TherapeuticsMD Announces Expiration of Tender Offer

TherapeuticsMD has previously stated that absent the successful closing of this transaction, the Company would likely be required to file for protection under Chapter 11. BOCA RATON, Fla.

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

Revlon

Eliem Therapeutics

Tuscan Holdings Corp II

Weber

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

TherapeuticsMD's $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run.

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Beam Global

Insignia Systems

JOANN

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

NEW YORK , June 6, 2022 /PRNewswire/ -- EW Healthcare Partners (together with its consolidated subsidiaries and affiliates "EW") announced today that its affiliate, Athene Merger Sub, Inc. ("Purchaser"), commenced the previously announced cash tender offer for all of the issued and outstanding shares of common stock of TherapeuticsMD, Inc. (Nasdaq: TXMD) ("TXMD" or the "Company") at a price of $10.00 per share, net to the seller, in cash, without interest and less applicable withholding taxes. The tender offer is being made pursuant to the merger agreement (the "Merger Agreement") executed on May 27, 2022 and announced by EW and TXMD on May 31, 2022, under which Purchaser will acquire TXMD in a transaction valued at approximately $177 million.

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

NEW YORK , June 1, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating TherapeuticsMD, Inc . (TXMD), relating to its proposed acquisition via a tender offer by an affiliate of EW Healthcare Partners.

Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TherapeuticsMD, Inc. (NasdaqGS: TXMD) to an affiliate of EW Healthcare Partners. Under the terms of the proposed transaction, shareholders of TherapeuticsMD will receive only $10.00 in cash for each share of TherapeuticsMD that they own. KSF is seeking to determine whether this consideration and the process th

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD

NEW YORK , May 31, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), in connection with the proposed acquisition of the Company via a tender offer by funds managed by an affiliate of EW Healthcare Partners.  Under the terms of the merger agreement, the Company's shareholders will receive $10.00 in cash for each share of TherapeuticsMD common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

TherapeuticsMD, Inc. (NASDAQ: TXMD) announced it entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners as part of a $177 million deal. These are the details.

Why EW Healthcare Partners Is Buying TherapeuticsMD (TXMD) In A $177 Million Deal

TherapeuticsMD Inc. (NASDAQ: TXMD) surged 300% after the women's healthcare firm announced the signing of a definitive agreement to be purchased by an EW Healthcare Partners affiliate. EW Healthcare Partners is a private equity company committed to investing in fast-growing healthcare firms.

Here is why TherapeuticsMD jumped 300%

Wilmington, Delaware--(Newsfile Corp. - May 31, 2022) - Rigrodsky Law, P.A. is investigating TherapeuticsMD, Inc. ("TXMD") (NASDAQ: TXMD) regarding possible breaches of fiduciary duties and other violations of law related to TXMD's agreement to be acquired by an affiliate of EW Healthcare Partners. Under the terms of the agreement TXMD's shareholders will receive $10.00 in cash for each share of TXMD common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-therapeuticsmd-inc.To...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TherapeuticsMD, Inc. Buyout

TherapeuticsMD (TXMD) stock is rocketing higher on Tuesday following news of an acquisition deal with EW Healthcare Partners. The post Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?

Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?

MILWAUKEE , May 31, 2022 /PRNewswire/ -- Ademi LLP is investigating TherapeuticsMD (NASDAQ: TXMD) for possible breaches of fiduciary duty and other violations of law in its transaction with EW Healthcare.  Click here to learn how to join the action: https://www.ademilaw.com/case/therapeuticsmd-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether TherapeuticsMD, Inc. has obtained a Fair Price in its transaction with EW Healthcare

TherapeuticsMD Inc (NASDAQ: TXMD) shares are surging Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners. EW Healthcare Partners will commence a tender offer to acquire all outstanding shares of.

Why TherapeuticsMD Stock Is Soaring Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of TherapeuticsMD, Inc. (NASDAQ: TXMD) to an affiliate of EW Healthcare Partners for $10.00 per share is fair to TherapeuticsMD shareholders. Halper Sadeh encourages TherapeuticsMD shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation c

TXMD Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of TherapeuticsMD, Inc. Is Fair to Shareholders

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD's board of directors, EW Hea

TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD

Chimerix

Immix Biopharma

Are these biotech penny stocks on your watchlist right now? The post Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch as Stocks Enter Bear Market

TherapeuticsMD Inc (NASDAQ: TXMD) shares are trading higher after FDA approved the supplemental application, including minor revisions to Annovera's in vitro release testing specification that allowed for normal manufacturing variability. The FDA approved Annovera in August.

Why TherapeuticsMD Shares Are Trading Higher Today

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced the FDA's approval of a supplemental New Drug Application (sNDA) for ANNOVERA. The sNDA included minor revisions to ANNOVERA's in vitro release testing specification that allowed for normal manufacturing variability. With the approval of the sNDA, the Company believes approximately 7,000 additional rings will be able to enter our sup

TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Operator Good afternoon, ladies and gentlemen. Thank you for joining us for Therapeutics MD's First Quarter 2020 Financial Results Conference Call.

TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q1 2022 Results - Earnings Call Transcript

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the first quarter ended March 31, 2022. “Our revenue performance during the quarter was impacted by ANNOVERA manufacturing challenges as anticipated, but we believe these obstacles peaked in the first quarter of 2022 and expect incremental improvement as the year progresses. I'm also pleased to report that the $

TherapeuticsMD Announces First Quarter 2022 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its first quarter 2022 financial results on Monday, May 16, 2022, after the closing of the U.S. financial markets. Executive management will host a conference call and webcast to discuss the results and provide a business update as follows: Date:   Monday, May 16, 2022 Time:   4:30 p.m. ET Telephone Access (US):

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

The TherapeuticsMD Inc (NASDAQ: TXMD) board has completed a 1-for-50 reverse stock split. These are the details.

News for TherapeuticsMD Stock (TXMD)